B of A Securities Maintains Neutral on Biogen, Lowers Price Target to $215

Benzinga Newsdesk www.benzinga.com Negative 67.7%

Neg 67.7% Neu 0% Pos 0%

B of A Securities analyst Jason Zemansky maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $217 to $215.